🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Nasopharyngeal Carcinoma

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC NCT06657690Phase 21 site📍 Zhuhai Sun Yat-sen University · Tests: Irinotecan liposome, S-1 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma NCT06976190Phase 31 site📍 Guangzhou Lepu Biopharma Co., Ltd. · Tests: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemoradiotherapy combined with immunotherapy LDRT and Chemoimmunotherapy in NPC With Liver Metastasis NCT06788002Phase 28 sites📍 Changsha📍 Changsha📍 Changsha Hunan Cancer Hospital · Tests: Low-dose radiotherapy combine with chemoimmunotherapy Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX Metastatic Nasopharyngeal Carcinoma NCT06886347Phase 11 site📍 Hangzhou Chen Xiaozhong · Tests: Penplimab Injection, Antitinib Hydrochloride Capsules, Gemcitabine A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) NCT06241599Phase 2, Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: GP/PFLL+AK104, GP/PFLL+placebo SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma NCT06323239Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: SBRT, Low-dose Radiotherapy (LDRT), Toripalimab, Gemcitabine, Cisplatin JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma NCT07690787Phase 21 site📍 Hong Kong Chinese University of Hong Kong · Tests: JS207, Paclitaxel, Capecitabine Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants NCT00898638n/a4 sites📍 Nashville📍 Nashville📍 Nashville Vanderbilt University Medical Center · Tests: biologic sample preservation procedure, medical chart review Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors NCT07625423Phase 11 site📍 Chengdu West China Hospital · Tests: EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers NCT00900419n/a1 site📍 Aurora University of Colorado, Denver · Tests: immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology, biopsy Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI NCT06831357n/a2 sites📍 Guangzhou📍 Guangzhou Sun Yat-sen University A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors NCT06475300Phase 21 site📍 Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" NCT01365169NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Exercise Intervention, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma NCT06194656Phase 22 sites📍 Shanghai📍 Shanghai Shanghai Institute Of Biological Products · Tests: HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclona… Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC NCT06472713Phase 21 site📍 Zhuhai Ming-Yuan Chen · Tests: Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma NCT05342792Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: PD-1 antibody, Capecitabine Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer NCT07188584Phase 31 site📍 Zhuhai Ming-Yuan Chen · Tests: Reduced-Target Radiotherapy, Conventional Full-Target Radiotherapy Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy NCT06676722Phase 22 sites📍 Xiamen📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: SBRT combined with Nimotuzumab followed by Tislelizumab Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma NCT06516133Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online a… Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial NCT07070479Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ming-Yuan Chen · Tests: Ivonescimab, Nimotuzumab, Irinotecan liposome, S-1, Mitoxantrone Hydrochloride Liposome Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. NCT06383780Phase 31 site📍 Guangzhou XIANG YANQUN · Tests: GP combined with Tislelizumab, TPC combined with Tislelizumab PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC NCT07235319Phase 35 sites📍 Guangzhou📍 Changsha📍 Fuzhou Sun Yat-sen University · Tests: Immediate locoregional radiotherapy, Salvage locoregional radiotherapy [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers NCT06479811Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy